VASCULAR ENDOTHELIAL GROWTH FACTORS IN HEART TRANSPLANT REJECTIONS

Aim: to determine the clinical significance of vascular endothelial growth factors VEGF-A, VEGF-D, PlGF-1 to assess the risk of cardiovascular complications in heart recipients. Materials and methods. 103 patients, aged 16 to 73 years, 85 males and 18 females. 65 recipients (47 men and 18 women) had dilated cardiomyopathy, 38 – coronary heart disease (CHD). The concentration of VEGF-A, VEGF-D, PlGF-1 was measured using xMAP technology with sets of reagents Simplex ProcartaPlex^™. Results. After HTx the level of VEGF-A significantly decreased, p = 0.001. There were no correlations between the levels of VEGF-A, VEGF-D and PlGF-1 with age, gender and diagnosis. After HTx VEGF-A level was higher in recipients with ACR than in those without it (p = 0.001). ACR frequency was significantly higher in patients with high VEGF-A level (≥316.5 pg/ml, RR = 5.8 ± 0.5, AUC = 0.779). After HTx PlGF-1 level was higher in recipients with ACR too (p = 0.039). ACR frequency was significantly higher in patients with high PlGF-1 level (≥5.33 pg/ml, RR = 1.8 ± 0.5, AUC = 0.65). There were no correlations between VEGF-D level with ACR and all three biomarkers with AMR. ACR frequency was significantly higher with both high VEGF-A and PlGF-1 levels (RR = 6.4). Conclusion. Serum levels of VEGF-A and PlGF-1 after HTx may be regarded as indicators of increased risk of ACR.

1. Lund LH, Edwards LB, Kucheryavaya AY, Dipchhand AI, Benden C, Christie JD et al. The registry of the International Society for Heart and Lung Transplantation: Thirtieth Official Adult Heart Transplant Report – 2013; Focus Theme: Age J Heart Lung Transplant. 2013; 32 (10): 951–964. DOI: 10.1016/j.healun.2013.08.006.PMID: 24054804.

2. Richter B, Koller L, Hohensinner PJ, Zorn G, Brekalo M, Berger R et al. A multi-biomarker risk score improves prediction of long-term mortality in patients with advanced heart failure. Int J Cardiol. 2013; 168 (2): 1251–1257. DOI: 10.1016/j.ijcard.2012.11.052. PMID: 23218577.

3. Frick M, Antretter H, Pachinger O, Pölzl G. Biomarker for diagnosis of rejection after heart transplantation Herz. 2010; 35 (1): 11–16. DOI: 10.1007/s00059-010 3309-3.PMID: 20140784. Labarrere CA, Jaeger BR. Biomarkers of heart transplant rejection: the good, the bad, and the ugly Transl Res. 2012; 159 (4): 238–251. DOI: 10.1016/j.trsl.2012.01.018. PMID: 22424428

4. Kimura K, Hashiguchi T, Deguchi T, Horinouchi Sh, Uto T, Oku H et al. Serum VEGF – as a prognostic factor of atherosclerosis. Atherosclerosis. 2007; 194: 182–188. DOI: http://dx.doi.org/10.1016/j.atherosclero- sis.2006.07.025.

5. Daly KP, Seifert ME, Chandraker A, Zurakowski D, Nohria A, Givertz MM et al. VEGF-C, VEGF-A and related angiogenesis factors as biomarkers of allograft vasculopathy in cardiac transplant recipients. J Heart Lung Transplant. 2013; 32 (1): 120–128. DOI: 10.1016/j.healun.2012.09.030.PMID: 23260712.

6. Шевченко ОП, Орлова ОВ, Шевченко АО, Туликов МВ. Неоангиогенез и коронарный атеросклероз: диагностическое значение нового биохимического маркера – плацентарного фактора роста P1GF – у больных ишемической болезнью сердца. Кардиология. 2006; 11: 9–15. Shevchenko OP, Orlova OV, Shevchenko AO, Tulikov MV. Neoangiogenez i koronarnyy ateroskleroz: diagnosticheskoe znachenie novogo biokhimicheskogo markera – platsentarnogo faktora rosta P1GF – u bol'nykh ishemicheskoy bolezn'yu serdtsa. Kardiologiya. 2006; 11: 9–15. [In Russ, English abstract].

7. Шевченко АО, Слесарева ЮС, Шевченко ОП. Лабораторная диагностика повреждения атеросклеротической бляшки у больных ишемической болезнью сердца: РАРР-А (обзор литературы). Клиническая лабораторная диагностика. 2011; 5: 3–10. Shevchenko AO, Slesareva YuS, Shevchenko OP. Laboratornaya diagnostika povrezhdeniya ateroskleroticheskoy blyashki u bol'nykh ishemicheskoy bolezn'yu serdtsa: РАРР-А (obzor literatury). Klinicheskaya laboratornaya diagnostika. 2011; 5: 3–10. [In Russ, English abstract].

8. Taimeh Z, Loughran J, Birks EJ, Bolli R. Vascular endothelial growth factor in heart failure. Nat. Rev. Cardiol. 2013; 10 (9): 519–530. DOI: 10.1038/ncardio.2013.94.

9. Geissler HJ, Dashkevich A, Fischer UM, Fries JW, Kuhn-Régnier F, Addicks K et al. First year changes of myocardial lymphatic endothelial markers in heart transplant recipients. Eur. J. Cardiothorac. Surg. 2006; 29 (5): 767–771. PMID: 16439147.

10. Cao Y, Ji WR, Qi P, Rosin A. Placenta growth factor: identification and characterization of a novel isoform generated by RNA alternative splicing. Biochem. Biophys. Res. Commun. 235 (3): 493–498. DOI: 10.1006/ bbrc.1997.6813. PMID 9207183.

11. Carnevalea D, Lembo G. Placental growth factor and cardiac inflammation. Trends Cardiovasc Med. 2012; 22 (8): 209–212. DOI: 10.1016/j.tcm.2012.07.022. PMID: 22925712.

12. Breen EJ, Polaskova V, Khan A. Bead-based multiplex immuno-assays for cytokines, chemokines, growth factors and other analytes: Median fluorescence intensities versus their derived absolute concentration values for statistical analysis. Cytokine. 2015; 71 (2): 188–198. DOI: 10.1016/j.cyto.2014.10.030. PMID: 25461398.

13. Ribatti D. The discovery of angiogenic growth factors: the contribution of Italian scientists. Vascular Cell. 2014; 6 (1): 8. DOI: 10.1186/2045-824X-6-8. PMID: 24690161.

14. Киселева ЕП, Крылов АВ,Старикова ЭА, Кузнецова СА. Фактор роста сосудистого эндотелия и иммунная система. Успехи современной биологии. 2009; 129 (4): 1–12. Kiseleva EP, Krylov AV, Starikova EA, Kuznetsova SA. Faktor rosta sosudistogo endoteliya i immunnaya sistema. Uspekhi sovremennoy biologii = Biology Bulletin Reviews. 2009; 129 (4): 1–12. [In Russ, English abstract].